High Neutralizing Potency of Swine Glyco-humanized Polyclonal Antibodies Against SARS-CoV-2
Overview
Authors
Affiliations
Heterologous polyclonal antibodies might represent an alternative to the use of convalescent plasma or monoclonal antibodies (mAbs) in coronavirus disease (COVID-19) by targeting multiple antigen epitopes. However, heterologous antibodies trigger human natural xenogeneic antibody responses particularly directed against animal-type carbohydrates, mainly the N-glycolyl form of the neuraminic acid (Neu5Gc) and the α1,3-galactose, potentially leading to serum sickness or allergy. Here, we immunized cytidine monophosphate-N-acetylneuraminic acid hydroxylase and α1,3-galactosyl-transferase (GGTA1) double KO pigs with the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor binding domain to produce glyco-humanized polyclonal neutralizing antibodies lacking Neu5Gc and α1,3-galactose epitopes. Animals rapidly developed a hyperimmune response with anti-SARS-CoV-2 end-titers binding dilutions over one to a million and end-titers neutralizing dilutions of 1:10 000. The IgG fraction purified and formulated following clinical Good Manufacturing Practices, named XAV-19, neutralized spike/angiotensin converting enzyme-2 interaction at a concentration <1 μg/mL, and inhibited infection of human cells by SARS-CoV-2 in cytopathic assays. We also found that pig GH-pAb Fc domains fail to interact with human Fc receptors, thereby avoiding macrophage-dependent exacerbated inflammatory responses and a possible antibody-dependent enhancement. These data and the accumulating safety advantages of using GH-pAbs in humans warrant clinical assessment of XAV-19 against COVID-19.
Antibody-dependent enhancement of coronaviruses.
Tao T, Tian L, Ke J, Zhang C, Li M, Xu X Int J Biol Sci. 2025; 21(4):1686-1704.
PMID: 39990674 PMC: 11844293. DOI: 10.7150/ijbs.96112.
Zhang T, Yang D, Tang L, Hu Y Mol Med Rep. 2024; 30(2).
PMID: 38940338 PMC: 11228696. DOI: 10.3892/mmr.2024.13272.
Poulakou G, Royer P, Evgeniev N, Evanno G, Shneiker F, Marcelin A Front Immunol. 2024; 15:1330178.
PMID: 38694503 PMC: 11061480. DOI: 10.3389/fimmu.2024.1330178.
Ciron C, Morice P, Rousse J, Roy P, Royer P, Gauthier O JCI Insight. 2023; 9(3).
PMID: 38085594 PMC: 10967460. DOI: 10.1172/jci.insight.166231.
Gaborit B, Vanhove B, Lacombe K, Guimard T, Hocqueloux L, Perrier L Open Forum Infect Dis. 2023; 10(11):ofad525.
PMID: 37942459 PMC: 10629360. DOI: 10.1093/ofid/ofad525.